Though we could not exclude the possibility that WDR5 expression is not a good prognostic marker in ER positive breast tumours, we should keep in mind that BreastMark uses PAM50 for tumour classification which is based on gene expression profiling but not immunohistochemical markers and may fail in reflecting the involvement of ER in such an association. This evidence concerns the gene WDR5 and neoplasm.